BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Events//NONSGML v1.0//EN
METHOD:PUBLISH
BEGIN:VEVENT
DTSTART;TZID="Pacific Time (US & Canada)":20241007T161000
DTEND;TZID="Pacific Time (US & Canada)":20241007T170000
SUMMARY:Department of Chemistry Seminar – Dr. Abhijit Date
LOCATION:Fulmer Hall
DESCRIPTION:Speaker:  Dr. Abhijit Date\n\nHost:  Dr. Anjali Sharma\n\nTitle: "NAno-scale Ionic Liquids (NAILs) to augment the delivery of drugs with poor solubility and/or permeability"\n\nAbstract:\n\nThe delivery of the majority of existing drugs and investigational drug candidates is limited due to suboptimal physicochemical characteristics such as high crystallinity, low and pH-dependent solubility, and suboptimal biopharmaceutical properties such as low permeability and bioavailability. Conventional delivery strategies such as solid dispersions and lipid nanoemulsions are often inefficient in improving the delivery of highly crystalline and hydrophobic/hydrophilic ionizable drugs due to their limited miscibility or solubility in polymeric and lipid vehicles. Ionic liquids (ILs) are organic salts with a melting point of < 100°C and depending upon the cations and anions involved in the formation, ILs can even be liquid at room temperature. Transformation of highly hydrophilic or hydrophobic ionizable drugs into amphiphilic ILs using pharmaceutically acceptable counterions followed by the development of nanoformulations of amphiphilic ILs is a novel and pharmaceutically viable strategy to improve their permeability, bioavailability, and efficacy. Our group has been working on the development of ILs of hydrophilic ionizable drugs with low permeability such as antidiabetic biguanides, nucleoside/nucleotide prodrugs, and highly crystalline hydrophobic ionizable drugs such as anthelmintic benzimidazoles and PROTACs to improve their solubility and/or permeability and delivery via oral, local or systemic routes of administration. We are utilizing this novel and translational approach to improve the treatment of cancer (prostate cancer and acute myeloid leukemia) and infectious diseases (cryptococcal meningitis, herpes simplex virus infections, and HIV).
BEGIN:VALARM
ACTION:DISPLAY
DESCRIPTION:REMINDER
TRIGGER;RELATED=START:-PT00H15M00S
END:VALARM
END:VEVENT
END:VCALENDAR